ArticleClinical drug investigation2024

A Pilot Study of the Effectiveness of a Short Course of Rifaximin 2200 mg/day on Abdominal Symptoms and its Effects on Quality of Life in Patients with Moderate to Severe Diarrhea-Predominant Irritable Bowel Syndrome.

Marjan Mokhtare et al.PubMed ↗Publisher ↗

No numbers read from the abstract.